Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26186797 | 0.76 | — | — | |
| SCHEMBL28147671 | 0.75 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL26599567 | 0.73 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3LMNACYP3A4 | |
| SCHEMBL26186836 | 0.73 | — | — | |
| SCHEMBL26186760 | 0.72 | — | — | |
| SCHEMBL23778380 | 0.71 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28968996 | 0.70 | CES1 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5037882 | 0.69 | MEN1 (0.40) | SLC6A2SLC6A4SLC6A3GABRA1GABRA5 | |
| SCHEMBL27074736 | 0.68 | SLC6A2 (0.32) | SLC6A2SLC6A4 | |
| SCHEMBL3006964 | 0.67 | KDM4E (0.38) | SLC6A2SLC6A4SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2023205801-A2 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-7615634-B2 | 4-aminopyrimidine-5-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7157455-B2 | 4-Aminopyrimidine-5-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060229330-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID J | 2006-10-12 | — | — | US | disclosed |
| EP-1628619-A2 | 4-AMINOPYRIMIDINE-5-ONE | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID JOSEPH (US) | 2004-08-19 | — | — | US | disclosed |
| WO-2004069139-A2 | 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | SLC6A2 4863/4885SLC6A4 4859/4885SLC6A3 4883/4885 |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK6 | SLC6A2 4854/4885SLC6A4 3790/4885SLC6A3 4694/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | SLC6A2 4863/4885SLC6A4 4859/4885SLC6A3 4883/4885 |
| US-20060229330-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK2 | SLC6A2 4627/4885SLC6A4 3083/4885SLC6A3 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.